A pilot pre-surgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients with muscle-Invasive, high-risk urothelial bladder carcinoma who are ineligible for cisplatin-based neoadjuvant chemotherapy.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jianjun Gao, Arlene O. Siefker-Radtke, Neema Navai, Matthew T. Campbell, Rebecca Slack, Charles Guo, Ashish M. Kamat, Surena F. Matin, John N. Papadopoulos, John C. Araujo, Amishi Yogesh Shah, Jorge M Blando, Luis M Vence, Fei Duan, Sreyashi Basu, Shalini Singh, Hao Zhao, Colin P.N. Dinney, Padmanee Sharma
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2890630295